Evercore ISI raises IQVIA stock price target to $220 on improved pharma demand

IQVIA Holdings (IQV) reported strong second-quarter 2025 financial results, exceeding market expectations with EPS of $2.81 and revenue of $4.017 billion. Following this performance and an improved demand environment across its pharmaceutical and biotech segments, Evercore ISI raised its price target on IQV to $220 from $180, maintaining an Outperform rating. The firm cited solid Research & Development Solutions (R&DS) revenues and better Technology & Analytics Solutions (TAS) results, projecting continued success into the second half of 2025, with the new target based on 12.5x 2026 EBITDA and 17x P/E.

Analysis

Evercore ISI has upgraded its price target for IQVIA Holdings (IQV) to $220 from $180, reaffirming its Outperform rating. This revision is directly linked to the company's strong second-quarter 2025 financial results, where it surpassed consensus estimates with an EPS of $2.81 against a projected $2.77 and revenue of $4.017 billion versus an anticipated $3.96 billion. The positive outlook is underpinned by an improved demand environment across IQVIA's key pharmaceutical and biotech client sectors, which has driven solid performance in its Research & Development Solutions (R&DS) and Technology & Analytics Solutions (TAS) divisions. Management's guidance for the third quarter is viewed as reasonable, with fourth-quarter growth expected to be bolstered by sustained demand and the strategic restart of a previously delayed trial. The new price target is based on forward-looking multiples of 12.5 times 2026 EBITDA and 17 times P/E, reflecting analyst confidence in IQVIA's structurally strong market position and momentum from an improving business cycle.

Key Decisions for Investors

• Given the dual catalysts of a significant earnings beat and a substantial analyst price target increase, investors should re-evaluate their positions in IQVIA, as the fundamental outlook has materially improved.
• Monitor the performance of the R&DS and TAS segments in upcoming quarters, as their continued strength is the core thesis behind the bullish analyst revision and management's positive guidance.
• Consider the new $220 price target, which implies notable upside from the current price, but also assess the underlying 17x P/E and 12.5x 2026 EBITDA multiples against industry peers and personal valuation criteria.